Somewhat Positive News Coverage Somewhat Unlikely to Affect Haemonetics (HAE) Stock Price

News headlines about Haemonetics (NYSE:HAE) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Haemonetics earned a news impact score of 0.20 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 45.2440042854595 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Several equities analysts recently commented on HAE shares. JMP Securities reiterated an “outperform” rating and issued a $72.00 target price on shares of Haemonetics in a research note on Wednesday, February 7th. TheStreet lowered Haemonetics from a “b” rating to a “c+” rating in a research note on Tuesday, February 6th. Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $78.00 target price for the company in a research note on Friday, February 9th. Morgan Stanley upgraded Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 target price for the company in a research note on Tuesday, January 2nd. Finally, Raymond James upgraded Haemonetics from an “underperform” rating to a “market perform” rating in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $71.33.

How to Become a New Pot Stock Millionaire

Shares of NYSE:HAE opened at $76.08 on Friday. The stock has a market cap of $4,048.12, a price-to-earnings ratio of 49.73, a PEG ratio of 3.30 and a beta of 0.89. The company has a quick ratio of 1.33, a current ratio of 1.82 and a debt-to-equity ratio of 0.14. Haemonetics has a 12 month low of $38.47 and a 12 month high of $76.38.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.18. The company had revenue of $234.04 million during the quarter, compared to analyst estimates of $227.79 million. Haemonetics had a positive return on equity of 12.39% and a negative net margin of 1.94%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 earnings per share. research analysts predict that Haemonetics will post 1.86 EPS for the current fiscal year.

Haemonetics announced that its Board of Directors has approved a stock buyback program on Tuesday, February 6th that permits the company to buyback $260.00 million in shares. This buyback authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

In other news, VP Dan Goldstein sold 518 shares of the company’s stock in a transaction dated Friday, April 6th. The stock was sold at an average price of $54.65, for a total value of $28,308.70. Following the completion of the sale, the vice president now owns 4,002 shares of the company’s stock, valued at $218,709.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michelle L. Basil sold 389 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $72.23, for a total value of $28,097.47. The disclosure for this sale can be found here. Insiders have sold 1,021 shares of company stock valued at $64,640 over the last 90 days. 1.20% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Haemonetics (HAE) Stock Price” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with's FREE daily email newsletter.

Leave a Reply